Kazia Therapeutics’ Shares Gain Following FDA Orphan Drug Status For Childhood Brain Cancer Drug
The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kazia Therapeutics’ (NASDAQ: KZIA) Paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
Kazia Therapeutics Concludes Mid-Stage Paxalisib Study In Brain Cancer
Kazia Therapeutics Limited (NASDAQ: KZIA) has completed a Phase 2 study of paxalisib in glioblastoma.
Kazia Therapeutics Announced Phase II Study of Paxalisib in Glioblastoma Achieved Final Completion; Data to Be Presented at Upcoming Conference
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that its phase II study of paxalisib in glioblastoma (NCT03522298) has been successfully completed.
Kazia Therapeutics Highlights Presentation Of Study Design, Biomarker Strategy For Ongoing Phase 1 Study Of EVT801 In Advanced Cancer At American Association For Cancer Research
Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)), a late stage, oncology-focused drug development company, is pleased to announce two presentations detailing the ongoing phase I study of the company's
Kazia Therapeutics Named Karen Krumeich as Chief Financial Officer
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the appointment of Karen Krumeich as Chief Financial Officer.